Cutaneous Necrosis after the Injection of Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis: A Rare Case Report

Document Type : Letter to Editor

Authors

1 Assistant Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Resident of Clinical Pharmacy, Student Research Committee AND Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

A 32-year-old man was diagnosed with cutaneous leishmaniasis, and intradermal Sodium Stibogluconate was injected for him. After two days, the injection site became erythematous, and a progressive necrotizing lesion appeared; hence, the patient diagnosed with soft tissue infection. Antibiotic therapy and debridement initiated for him. Cutaneous adverse effect of Sodium Stibogluconate is not common, and among them, coetaneous necrosis is rare. Sodium Stibogluconate is a mixture of complex compound, and it is not a simple medicine. A probable mechanism of necrosis formation in this case is hypersensitivity reactions. Hence, it is suggested to avoid intradermal injection of this medicine, especially those brands which do not claim intradermal injection allowance.

Keywords

References

  1. Oster CN, Chulay JD, Hendricks LD, Pamplin CL, III, Ballou WR, Berman JD, et al. American cutaneous leishmaniasis: A comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985; 34(5): 856-60.
  2. Bermudez H, Rojas E, Garcia L, Desjeux P, Dujardin JC, Boelaert M, et al. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann Trop Med Parasitol 2006; 100(7): 591-600.
  3. Faghihi G, Basiri A, Pourazizi M, Abtahi-Naeini B, Saffaei A. Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review. J Res Pharm Pract 2015; 4(2): 99-103.
  4. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988; 82(1): 69-72.
  5. Roberts WL, Rainey PM. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob Agents Chemother 1993; 37(9): 1842-6.
Journal of Isfahan Medical School
Volume 37, Issue 524 - Serial Number 524
March and April 2019
Pages 435-437

Files

History

  • Receive Date: 25 May 2019
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics